SPECIAL REQUIREMENTS SECTION OF RFA-XX-OI-0ll
1. Plans to share research resources. All vectors for transgenic production and mouse strains generated over the past several years have been distributed freely to the broader academic community, either before or immediately on publication. Indeed we have supplied over 250 requesting laboratories with either vectors, mice, or both. Requestees typically receive the desired reagents within two weeks to two months of their request, depending on their chronological position in the queue. The infrastructure for this rapid sharing of newly developed reagents (both vectors and mice) continues to be in place in my lab and supported by the Office of Technology and Licensing, APPLICANT INSTITUTION (see attached letter by XXXXX).
2. Intellectual property rights. Consistent with APPLICANT INSTITUTION's policy on intellectual property rights (see attached letter by XXX), my lab will make available any and all strains of transgenic mice produced under this grant for use at other academic or not-for-profit institutions at no cost except for standard maintenance and transportation expenses. (APPLICANT INSTITUTION) will reserve the right to use these reagents for educational, research, or other nonbusiness purposes. APPLICANT INSTITUTION may establish a non-exclusive commercial license granting APPLICANT INSTITUTION's rights to use such animals at specific for-profit entities; in these cases, APPLICANT INSTITUTION will maintain the right to grant non-exclusive licenses for use of these materials by academic or not-for-profit institutions.
Transfer of materials to not-for-profit entities will be implemented under terms no more restrictive than the Uniform Biological Materials Transfer Agreement (see example of the APPLICANT INSTITUTION simple letter MTA attached in the appendix). Transfer of materials to for-profit entities will be mediated through the APPLICANT INSTITUTION Office of Technology and Licensing, and typically involves a simple license agreement with execution or annual fees as deemed appropriate, but in no way prohibitive to the ready distribution of these reagents.
Intellectual property rights as pertains to ABC-XYX reagents. The Non-Profit Institute holds a patent on the use of ABC in mammalian cells. They have made clear that any reagents harboring ABC or XYZsequences can be freely distributed amongst academic, not-for-profit institutions. Such transfers would be done under a joint APPLICANT INSTITUTION/ Non-Profit Institute simple letter MTA (see attached letter from Dr. XXX, Office of Technology and Licensing, APPLICANT INSTITUTION ). Should reagents be transferred to for-profit institutions, an inter-institutional license (APPLICANT INSTITUTION / Non-Profit Institute) will be drafted with execution or annual fees as deemed appropriate, but in no way prohibitive to the ready distribution of these reagents. Those reagents generated in collaboration with Dr. SSSS would require a inter-institutional MTA involving APPLICANT INSTITUTION / Non-Profit Institute /Non-Profit Research Center. These simple agreements are already in place.
Intellectual property rights as pertains to @@@reagents. For-Profit Company holds a patent on the use of @@@ in @@@@. The memorandum of understanding between For-Profit Company and PHS makes it clear that any and all @@@ containing reagents generated under this grant can be readily shared with the broader academic community under a simple MTA, and do not infringe on the uses under restriction (namely: @@@@, @@@ and @@@) Should our reagents be transferred to for-profit institutions, an inter-institutional license (APPLICANT INSTITUTION/ For-Profit Company) will be drafted with execution or annual fees as deemed appropriate. Of course, current For-Profit Company licensing issues as surrounds for-profit institutions would have to be settled between that institution and For-Profit Company.
Intellectual property rights as pertains to the locus. The Non-Profit Research Center holds a license on use of sequences. This license stipulates free use for academic, not-for-profit institutions and involves a simple letter MTA. Those reagents generated in collaboration with Dr. SSSS that incorporate sequences will require an inter-institutional MTA involving APPLICANTINSTITUTIONMedicalSchool and Non-Profit Research Center. These simple agreements are currently in place. Should reagents be transferred to for-profit institutions, an inter-institutional license (APPLICANT INSTITUTION Medical School/Non-Profit Research Center) will be drafted with execution or annual fees as deemed appropriate, but in no way prohibitive to the ready distribution of these reagents.